Table 1 Structure of the analysed groups
From: Standard versus extended pneumonectomy for lung cancer: what really matters?
Group 1 | Group 2 | Group 3 | P | |||||
|---|---|---|---|---|---|---|---|---|
Age (mean ± standard deviation) (years) | 58.9 ± 7.8 | 58.7 ± 6.2 | 51.4 ± 5.7 | <0.05 | ||||
Side (right/left) | 38/44 | 22/16 | 41/3 | G1:G2: P > 0.05 | ||||
G1 + G2 vs G3: P < 0.05 | ||||||||
n (%) | n (%) | n (%) | ||||||
Operative stage | Ia | 2 | (2.4) | 1 | (2.6) | 0 | (0) | >0.05 |
Ib | 7 | (8.5) | 0 | (0) | 0 | (0) | ||
IIa | 17 | (20.7) | 3 | (7.9) | 0 | (0) | ||
IIb | 8 | (9.8) | 7 | (18.4) | 0 | (0) | ||
IIIa | 38 | (46.4) | 25 | (65.8) | 26 | (59) | ||
IIIb | 10 | (12.2) | 2 | (5.3) | 18 | (41) | ||
COPD | Mild | 10 | (12.2) | 4 | (10.5) | 5 | (11.3) | COPD total |
Moderate | 9 | (10.9) | 4 | (10.5) | 9 | (20.5) | G1: G2:G3 | |
Severe | 0 | (0) | 0 | (0) | 1 | (2.2) | P = 0.196 | |
COPD total | 19 | (23.1) | 8 | (21) | 15 | (34) | ||
Cardiovascular risk | 10 | (12.2) | 5 | (13.2) | 6 | (13.6) | >0.05 | |
Other comorbidities* | 10 | (12.2) | 5 | (13.2) | 5 | (11.4) | >0.05 | |
Neoadjuvant therapy | 22 | (26.8) | 12 | (31.6) | 5 | (11.4) | G1:G2: P > 0.05 | |
G1 + G2 vs G3: P < 0.05 | ||||||||
Adjuvant therapy | 30 | (36.5) | 15 | (39.4) | 19 | (43.2) | >0.05 | |
Tumour histology | Squamous | 55 | (67) | 26 | (68.4) | 35 | (79.6) | >0.05 |
Adeno Ca | 24 | (29.2) | 10 | (26.3) | 5 | (11.4) | ||
Other | 3 | (3.6) | 2 | (5.3) | 4 | (9.1) | ||
T component | T1 | 9 | (10.9) | 4 | (10.5) | 0 | (0) | G1 + G2 vs G3 |
T2 | 37 | (45.1) | 10 | (26.3) | 0 | (0) | <0.05 | |
T3 | 21 | (25.6) | 19 | (50) | 16 | (36.4) | ||
T4 | 15 | (18.3) | 5 | (13.2) | 18 | (32.14) | ||
N2 lesions | 25 | (30.5) | 12 | (31.6) | 22 | (50) | <0.05 | |